Rate of progression differs in frontotemporal dementia and Alzheimer disease

K. Rascovsky, David P. Salmon, A. M. Lipton, J. B. Leverenz, Charles DeCarli, W. J. Jagust, C. M. Clark, M. F. Mendez, D. F. Tang-Wai, N. R. Graff-Radford, D. Galasko

Research output: Contribution to journalArticle

129 Citations (Scopus)

Abstract

Objective: To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study. Background: Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs. Methods: Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation. Survival and rates of cognitive and functional decline were compared. Results: Patients with FTD had significantly shorter survival from initial evaluation to death than patients with AD (FTD = 4.2 years, AD = 6.0 years; log-rank test = 5.17, p < 0.05), and they declined significantly faster over one year on the MMSE (mean annual rate of change: -6.7 points for FTD vs -2.3 points for AD). A significantly greater proportion of patients with FTD were impaired in basic activities of daily living (ADLs) at initial evaluation, and lost the capacity for independent or minimally-assisted ADLs over the subsequent year. Conclusions: The results are consistent with shorter survival and faster rates of cognitive and functional decline in patients with frontotemporal dementia (FTD) compared to those with Alzheimer disease (AD). This suggests that FTD follows a more malignant disease course than AD once dementia is clinically recognized.

Original languageEnglish (US)
Pages (from-to)397-403
Number of pages7
JournalNeurology
Volume65
Issue number3
DOIs
StatePublished - Aug 9 2005

Fingerprint

Frontotemporal Dementia
Alzheimer Disease
Survival Rate
Activities of Daily Living
Autopsy
Benchmarking
Multicenter Studies
Dementia
Guidelines
Education

ASJC Scopus subject areas

  • Neuroscience(all)

Cite this

Rascovsky, K., Salmon, D. P., Lipton, A. M., Leverenz, J. B., DeCarli, C., Jagust, W. J., ... Galasko, D. (2005). Rate of progression differs in frontotemporal dementia and Alzheimer disease. Neurology, 65(3), 397-403. https://doi.org/10.1212/01.wnl.0000171343.43314.6e

Rate of progression differs in frontotemporal dementia and Alzheimer disease. / Rascovsky, K.; Salmon, David P.; Lipton, A. M.; Leverenz, J. B.; DeCarli, Charles; Jagust, W. J.; Clark, C. M.; Mendez, M. F.; Tang-Wai, D. F.; Graff-Radford, N. R.; Galasko, D.

In: Neurology, Vol. 65, No. 3, 09.08.2005, p. 397-403.

Research output: Contribution to journalArticle

Rascovsky, K, Salmon, DP, Lipton, AM, Leverenz, JB, DeCarli, C, Jagust, WJ, Clark, CM, Mendez, MF, Tang-Wai, DF, Graff-Radford, NR & Galasko, D 2005, 'Rate of progression differs in frontotemporal dementia and Alzheimer disease', Neurology, vol. 65, no. 3, pp. 397-403. https://doi.org/10.1212/01.wnl.0000171343.43314.6e
Rascovsky, K. ; Salmon, David P. ; Lipton, A. M. ; Leverenz, J. B. ; DeCarli, Charles ; Jagust, W. J. ; Clark, C. M. ; Mendez, M. F. ; Tang-Wai, D. F. ; Graff-Radford, N. R. ; Galasko, D. / Rate of progression differs in frontotemporal dementia and Alzheimer disease. In: Neurology. 2005 ; Vol. 65, No. 3. pp. 397-403.
@article{ecfb1a801abe4d3cb3e6f4b63f458a48,
title = "Rate of progression differs in frontotemporal dementia and Alzheimer disease",
abstract = "Objective: To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study. Background: Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs. Methods: Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation. Survival and rates of cognitive and functional decline were compared. Results: Patients with FTD had significantly shorter survival from initial evaluation to death than patients with AD (FTD = 4.2 years, AD = 6.0 years; log-rank test = 5.17, p < 0.05), and they declined significantly faster over one year on the MMSE (mean annual rate of change: -6.7 points for FTD vs -2.3 points for AD). A significantly greater proportion of patients with FTD were impaired in basic activities of daily living (ADLs) at initial evaluation, and lost the capacity for independent or minimally-assisted ADLs over the subsequent year. Conclusions: The results are consistent with shorter survival and faster rates of cognitive and functional decline in patients with frontotemporal dementia (FTD) compared to those with Alzheimer disease (AD). This suggests that FTD follows a more malignant disease course than AD once dementia is clinically recognized.",
author = "K. Rascovsky and Salmon, {David P.} and Lipton, {A. M.} and Leverenz, {J. B.} and Charles DeCarli and Jagust, {W. J.} and Clark, {C. M.} and Mendez, {M. F.} and Tang-Wai, {D. F.} and Graff-Radford, {N. R.} and D. Galasko",
year = "2005",
month = "8",
day = "9",
doi = "10.1212/01.wnl.0000171343.43314.6e",
language = "English (US)",
volume = "65",
pages = "397--403",
journal = "Neurology",
issn = "0028-3878",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Rate of progression differs in frontotemporal dementia and Alzheimer disease

AU - Rascovsky, K.

AU - Salmon, David P.

AU - Lipton, A. M.

AU - Leverenz, J. B.

AU - DeCarli, Charles

AU - Jagust, W. J.

AU - Clark, C. M.

AU - Mendez, M. F.

AU - Tang-Wai, D. F.

AU - Graff-Radford, N. R.

AU - Galasko, D.

PY - 2005/8/9

Y1 - 2005/8/9

N2 - Objective: To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study. Background: Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs. Methods: Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation. Survival and rates of cognitive and functional decline were compared. Results: Patients with FTD had significantly shorter survival from initial evaluation to death than patients with AD (FTD = 4.2 years, AD = 6.0 years; log-rank test = 5.17, p < 0.05), and they declined significantly faster over one year on the MMSE (mean annual rate of change: -6.7 points for FTD vs -2.3 points for AD). A significantly greater proportion of patients with FTD were impaired in basic activities of daily living (ADLs) at initial evaluation, and lost the capacity for independent or minimally-assisted ADLs over the subsequent year. Conclusions: The results are consistent with shorter survival and faster rates of cognitive and functional decline in patients with frontotemporal dementia (FTD) compared to those with Alzheimer disease (AD). This suggests that FTD follows a more malignant disease course than AD once dementia is clinically recognized.

AB - Objective: To compare survival and rates of cognitive and functional decline in patients with autopsy-confirmed frontotemporal dementia (FTD) and Alzheimer disease (AD) in a large multicenter study. Background: Despite advances in the clinical characterization of FTD, little is known about its rate of progression. Characterizing survival and rate of decline in FTD is important because it can provide prognostic guidelines and benchmarks to use in the evaluation of disease-modifying drugs. Methods: Seventy patients with FTD and 70 patients with AD who were followed by seven Alzheimer disease research centers until confirmation of diagnosis at autopsy were matched for overall age, education, and Mini-Mental State Examination (MMSE) score at initial evaluation. Survival and rates of cognitive and functional decline were compared. Results: Patients with FTD had significantly shorter survival from initial evaluation to death than patients with AD (FTD = 4.2 years, AD = 6.0 years; log-rank test = 5.17, p < 0.05), and they declined significantly faster over one year on the MMSE (mean annual rate of change: -6.7 points for FTD vs -2.3 points for AD). A significantly greater proportion of patients with FTD were impaired in basic activities of daily living (ADLs) at initial evaluation, and lost the capacity for independent or minimally-assisted ADLs over the subsequent year. Conclusions: The results are consistent with shorter survival and faster rates of cognitive and functional decline in patients with frontotemporal dementia (FTD) compared to those with Alzheimer disease (AD). This suggests that FTD follows a more malignant disease course than AD once dementia is clinically recognized.

UR - http://www.scopus.com/inward/record.url?scp=23244452355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23244452355&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000171343.43314.6e

DO - 10.1212/01.wnl.0000171343.43314.6e

M3 - Article

C2 - 16087904

AN - SCOPUS:23244452355

VL - 65

SP - 397

EP - 403

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 3

ER -